In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...

February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three ...

There are many stocks with exceptional dividends to check out. Here are three dividend stocks to double up on right now.

Earnings season is when investors get a progress report about the companies in their portfolio or on their watchlist. An earnings report is generally a lagging indicator. That’s because the headline ...

Invest in essential sectors like consumer staples and energy to beat inflation. See why these stocks offer reliable dividends ...

Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed. Read my analysis ...

The company's immunology drugs, Skyrizi and Rinvoq, exceeded sales forecasts by 5% and 8%, respectively, effectively compensating for the 13% decline in Humira sales. This performance underscores ...

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic arthritis, according to data published in Therapeutic Advances in Musculoskeletal ...

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

SAN FRANCISCO -- The pediatric Crohn's disease exclusion diet was associated with clinical remission for children with good ...